New molecular platform to access intracellular targets across a broad range of tumor cell types
Opens up new range of therapeutic opportunities for difficult-to-treat cancers
INGELHEIM, Germany & BERLIN -- (BUSINESS WIRE) --
Boehringer Ingelheim today announced that it acquired ICD Therapeutics. The acquisition includes rights to ICD’s innovative MacroDel biologics-delivery platform. Boehringer Ingelheim will employ this platform for the development of novel therapeutics in collaboration with nanoPET Pharma GmbH, a former shareholder of ICD Therapeutics. Further details of the acquisition are not being disclosed.
“Boehringer Ingelheim’s collaboration with nanoPET Pharma has the potential to eliminate the hurdle that many cancer biologics face: getting access to targets inside tumor cells,” said Norbert Kraut, Ph.D., Global Head of Cancer Research, Boehringer Ingelheim. “We will use ICD’s MacroDel technology to develop first-in-class potential drug candidates for intracellular targets across a variety of tumor types, for the benefit of patients who so far have no or only inadequate treatment options.”
Engineered proteins and peptides offer great potential to block protein-protein interactions inside cancer cells, but their large size is generally assumed to prevent intracellular delivery. ICD’s MacroDel technology exploits transporter proteins in the cell membrane to deliver such drug candidates inside tumor cells. This opens up therapeutic targets that would be otherwise inaccessible.
“nanoPET Pharma looks forward to collaborating with Boehringer Ingelheim on the pre-clinical refinement of ICD’s MacroDel to achieve effective intracellular delivery of macromolecules such as peptides and proteins,” said Andreas Briel, Ph.D., Managing Director of nanoPET Pharma GmbH. “We are excited to contribute to Boehringer Ingelheim’s discovery and development of innovative medicines for patients in need.”
More about MacroDel
Tree-like highly branched molecules known as dendrimers form a fundamental component of the MacroDel platform. The size, shape and electrical charge of this structure permit it to grasp large therapeutic biological molecules. After binding with the biologic, the resulting compound selectively interacts with transporter proteins known to be highly expressed on tumor cell wall membranes. These transporters help “carry” the compound through the membrane and into the cell. The medicinal cargo is then in position to disrupt the disease process in a precise manner at a molecular level.
A prior investment from Boehringer Ingelheim’s Venture Fund (BIVF) supported ICD’s development of the MacroDel technology. The BIVF strategically invests in groundbreaking therapeutics-focused biotechnology companies to enable development of their technologies for therapeutic applications that have potential for strategic partnerships with Boehringer Ingelheim or other pharmaceutical partners.
全国政协:束昱辉政协全国委员会委员资格被撤
“第三届中国最美露营地颁奖盛典” 在京隆重
2020中国全过程工程咨询行业综合实力百强榜单
游历于艺术界的资深书法家陆林深-曾探访美、
文旅融合绘就“诗与远方”
Enviva森林保护基金公布2022年资助对象
广饶公安千里追踪破获侵犯公民个人信息案!
上饶:弘扬爱卫新风尚 培养健康新生活
LambdaTest为其端到端测试编排平台Hyper
Notice of ABB’s Annual Meeting
上饶:早稻机收减损促增产 颗粒归仓保丰收
滨州市滨城区玉龙湖小学2015级1班家长进进课堂
银河娱乐集团2020年第二季度及中期业绩
国际护士节:礼赞无私大爱 致敬白衣天使
GSMA:全球所有领先的物联网运营商即日起将提
皇尊庄园2021年度安全工作会议召开
健康宅家,知识战疫,咪咕中信书店价值万元精
青岛活动搭建、冰激凌机租赁、亲子活动道具信
迪拜水电局开放2022年水资源、能源、环保科技
iEnglish英语风采秀助力11岁男孩的“外交官之梦
Blue Yonder助力零售商打造个性化全渠道商务体验
Elliptic Labs与传音智能手机联手
Rambus推出6400MT/s DDR5寄存时钟驱动器
83天!200亿件!快递业务量增长再提速